Jazz Pharmaceuticals JAZZ Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$368.44M-180% | -$404.8M-203% | $482.24M+45.8% | ||
| $40.34M+13.6% | $41.64M+27.1% | $41.72M+35.1% | $39.62M+28.7% | $35.5M+16.4% | ||
| $297.93M+17.2% | $291.13M+17.4% | $290.47M+25.9% | $262.1M+15.4% | $254.3M+9.6% | ||
| -$467.37M-152% | -$444.97M-114% | -$384.02M-58.8% | -$177.01M+31.0% | -$185.74M+28.7% | ||
| —— | —— | —— | —— | $0— | ||
| $178.78M+441% | $106.28M+384% | $40.47M-58.5% | $11.73M-87.5% | -$52.46M-159% | ||
| $135.96M+99.1% | $93.76M+106% | $112.43M+298% | $89.8M+275% | $68.3M+242% | ||
| —— | —— | —— | —— | —— | ||
| -$111.8M— | $77.1M— | $80.66M— | $5.4M— | —— | ||
| -$81.68M-276% | -$29.03M-158% | $22.25M— | $44.92M— | $46.48M— | ||
| $37.32M+208% | $28.02M+168% | -$34.3M+25.1% | -$32.67M+30.1% | -$34.53M-18.0% | ||
| —— | —— | -$8.06M— | -$11.14M— | $1.56M— | ||
| —— | —— | $37.17M— | $26.5M— | -$16.6M— | ||
| $672.51M+7.4% | $654.61M+4.4% | $643.77M+3.8% | $632.86M+2.5% | $625.98M+1.9% | ||
| $1.33B-14.4% | $1.36B-2.9% | $1.39B+19.5% | $1.32B+22.6% | $1.56B+50.1% | ||
| $64.55M+43.2% | $58.75M+54.3% | $55.31M+58.5% | $50.92M+79.3% | $45.07M+66.6% | ||
| $1.89B+37.9% | $1.83B+40.2% | $1.79B+87.4% | $1.28B+26.1% | $1.37B+79.1% | ||
| $1.57B+51.7% | $1.36B+60.9% | $1.47B+82.6% | $1.43B+203% | $1.04B+165% | ||
| —— | —— | —— | —— | $0— | ||
| $83.5M+234% | $108.5M— | $55M— | $25M— | $25M— | ||
| -$1.22B— | -$1.51B— | -$1.33B— | —— | —— | ||
| $129.26M+308% | $107.86M+422% | $31.87M+57.0% | $31.16M+20.8% | $31.65M+23.0% | ||
| $111.62M+47.5% | $75.22M+30.2% | $77.23M+39.5% | $75.02M+34.8% | $75.66M+32.8% | ||
| -$213.82M— | -$948.82M— | —— | —— | —— | ||
| $4.46M+159% | $6.56M+491% | $4.23M+76.2% | $7.1M+521% | $1.72M+293% | ||
| —— | —— | —— | -$165.92M-326% | $418.48M+51.9% | ||
| —— | $248.55M-21.0% | $265.12M-17.0% | $281.69M-13.1% | $298.25M-9.2% | ||
| —— | $121.81M+6.0% | $120.08M-8.1% | $118.36M-19.2% | $116.63M-28.1% | ||
| $672.51M+7.4% | $654.61M+4.4% | $643.77M+3.8% | $632.86M+2.5% | $625.98M+1.9% | ||
| $40.34M+13.6% | $41.64M+27.1% | $41.72M+35.1% | $39.62M+28.7% | $35.5M+16.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $155.55M+14.4% | $147.95M+9.6% | $145.14M+12.0% | $139.82M+11.5% | $135.97M+13.4% | ||
| $20.14M-39.1% | $32.54M+48.1% | $30.31M+21.2% | $32.69M+39.8% | $33.09M+40.2% | ||
| —— | —— | -$8.06M— | -$11.14M— | $1.56M— | ||
| $28.01M+9.2% | $19.11M-31.2% | $26.89M+39.7% | $21.34M+13.8% | $25.66M+58.4% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $83.5M+234% | $108.5M— | $55M— | $25M— | $25M— | ||
| —— | —— | —— | —— | —— | ||
| $1.57B+51.7% | $1.36B+60.9% | $1.47B+82.6% | $1.43B+203% | $1.04B+165% | ||
| —— | —— | —— | —— | $0— | ||
| $129.26M+308% | $107.86M+422% | $31.87M+57.0% | $31.16M+20.8% | $31.65M+23.0% | ||
| $31M-96.0% | $781M+2,419% | $781M+2,419% | $781M+2,419% | $781.05M+2,420% | ||
| —— | $121.81M+6.0% | $120.08M-8.1% | $118.36M-19.2% | $116.63M-28.1% | ||
| $1.27B-16.1% | $1.3B-4.5% | $1.34B+18.3% | $1.27B+21.1% | $1.51B+49.6% | ||
| $1.27B-16.1% | $1.3B-4.5% | $1.34B+18.3% | $1.27B+21.1% | $1.51B+49.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Jazz Pharmaceuticals generate?
- Jazz Pharmaceuticals (JAZZ) generated $1.3B in operating cash flow over the trailing twelve months.
- What is Jazz Pharmaceuticals's free cash flow?
- After $64.6M of capital expenditures, Jazz Pharmaceuticals's free cash flow was $1.3B over the trailing twelve months, down 16.1% year over year.
- Where does Jazz Pharmaceuticals's cash flow data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
